World Renal Cell Carcinoma Drugs Market Analysed in New RNCOS E-Services Report Published at

29 Feb 2016 • by Natalie Aster

LONDON – There are a great number of factors, such as hypertension, smoking, unhealthy eating habits and family history, that raise the risks for occurrence of renal cell carcinoma (otherwise termed renal adenocarcinoma). Diverse tests, such as ultrasound, urine analysis, intravenous pyelogram, computerized axial tomography scan (CAT scan), magnetic resonance imaging (MRI) and biopsy, are currently available that can help in early detection of this disease. Drugs such as Votrient, Sutent, Nexavar and Inlyta, among others, are used to treat renal cell carcinoma. The most recent addition to this lot is Bristol-Myers Squibb’ Opdivo. Furthermore, there are many more drugs in development, which are likely to support the market’s growth. 

The renal cell carcinoma drugs market is poised to surpass the USD 4 billion mark by 2020-end. North America is grabbed the largest share of the market owing to great number of commercially available drug products to treat renal cell carcinoma, huge patient pool, favourable terms of healthcare insurance coverage, and impressive healthcare systems customised for the pharmaceutical industry, among others. However, the APAC market is expected to witness the most rapid growth in the years to come due to improving healthcare institutions in the region in tandem with the expanding patient pool.

New research study “Global Renal Cell Carcinoma Drugs Market 2020” elaborated by RNCOS E-Services provides a detailed analysis of the market for these drugs. The report throws light on the market’s current performance and forecasts its development in the coming years. The study gives information and revenues of the key branded drugs in the market for the disease discussed. The segmentation of renal cell carcinoma drugs market is done based on different geographies. It also gives an overview of RCC drugs at different stages of clinical trials. In addition, the report presents shrewd insights into the major drivers and challenges, latest developments and trends, and strategic alliances influencing the growth in the industry. The study discusses some of the prominent global market players along with an analysis of their market shares. It offers a brief business description of each player their business segments, products and latest developments. Moreover, a granular analysis of the companies’ strengths and weaknesses is provided in the study.

Report Details:

Global Renal Cell Carcinoma Drugs Market 2020
Published: February, 2016 
Pages: 65
Price: US$ 1,500.00

More studies by this publisher can be found at RNCOS E-Services page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970